French pharmaceutical firm Neovacs has completed enrollment for a Phase 2b clinical trial (IFN-K-002) to evaluate the efficacy and safety of IFNα-Kinoid to treat systemic lupus erythematosus (SLE). “The completion of enrollment is an important milestone for our IFN Kinoid program and confirms the interest of leading clinicians conducting our trial in this novel…
News
New York researcher Virginia Pascual has received the $150,000 Lupus Insight Prize for work that promises to improve our understanding of events leading to the disease’s flare-ups. Pascual is a pioneer in lupus biomarkers, or molecular signals of the disease. She was recently appointed founding director of the Gale and…
Neuropsychiatric symptoms in people with systemic lupus erythematosus may be caused by increased levels of the inflammatory molecule interferon-alpha in their brains, according to a study published in the journal Nature. But a treatment now in clinical trials may be able to arrest the processes that lead to those symptoms. The…
A combination of voclosporin and standard therapy eliminated the inflamed-kidney condition lupus nephritis in twice as many patients as those who received standard care alone, according to a Phase 2b clinical trial. The voclosporin combo also lengthened the time it took for lupus nephritis to re-emerge, its maker, Aurinia Pharmaceuticals,…
A Phase 2a trial (NCT02185040) evaluating Celgene International‘s CC-220 in systemic lupus erythematosus (SLE) reports promising results, according to data presented at the Annual European Congress of Rheumatology (EULAR) 2017, held June 14-17 in Madrid. “While the outlook for patients with lupus has improved over the last 75 years, treatment…
Patients with active systemic lupus erythematosus (SLE) were able to control their disease with Benlysta (belimumab) plus standard of care (prednisone), pharmaceutical giant GSK said in announcing the results from a 10-year continuation study. GSK presented the study’s results at the Annual European Congress of Rheumatology (EULAR 2017), held June 14-17 in Madrid. U.S.
The Lupus Foundation of America and American College of Rheumatology have started a campaign to let African-American and Hispanic women know that they are at higher risk of developing lupus. The aim of the “Be Fierce, Take Control” campaign is to raise awareness of the signs and symptoms of lupus among the…
MyHealthTeams, a San Francisco-based start-up that creates social networks for people with lupus and other chronic diseases, has obtained a second multi-million-dollar round of financing from Qiming Venture Funds. The $7.3 million came from a $100 million fund that Seattle-based Qiming U.S. Healthcare Fund created to back American…
Exagen Diagnostics has developed a blood test to keep tabs on the conditions of people with lupus and the kidney disease lupus nephritis. The company has made the test, which it calls the AVISE SLE Monitor, available to doctors throughout the United States. The New York State Department of Health has conditionally approved the test,…
Lupus patients with a history of kidney disease, but now in remission, should not be advised against a wanted pregnancy — even if they show serologic activity, or positive anti-double-stranded DNA antibodies and low complement levels (C4), results from the PROMISSE trial show. Women in the study based on these findings, “…
Recent Posts
- Caught without my helpful spend-a-night bag
- AMETHYST trial of litifilimab making “strong progress,” Biogen says
- What reasonable workplace accommodations actually look like
- How to mitigate the sense of failure that can arise during a lupus flare
- What to remember if you’re dating with a chronic illness